Brief: Uniqure Announces FDA Clearance Of Investigational New Drug Application For AMT-260 Gene Therapy For Refractory Mesial Temporal Lobe Epilepsy
05/09/2023 12:17
Sept 5 (Reuters) - Uniqure NV UQ1.F :
* UNIQURE ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW
DRUG
APPLICATION FOR AMT-260 GENE THERAPY FOR REFRACTORY MESIAL
TEMPORAL LOBE EPILEPSY
* UNIQURE NV - CLINICAL TRIAL IS EXPECTED TO BEGIN PATIENT
SCREENING IN Q4 OF 2023
Source text for Eikon: ID:nGNX58pgPR
Further company coverage: UQ1.F
((Reuters.briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal